Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal ISM (Intisari Sains Medis) : Jurnal Kedokteran
Ronald Natawidjaja
Residen Bedah Umum, Universitas Udayana- RSUP Sanglah, Bali
Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Faktor risiko yang mempengaruhi length of stay pasien kanker solid dengan febrile neutropenia pasca kemoterapi neoadjuvant/terapeutik di Ruang Isolasi RSUP Sanglah, Bali Ronald Natawidjaja; Ida Bagus Tjakra Wibawa Manuaba; Putu Anda Tusta Adiputra
Intisari Sains Medis Vol. 10 No. 1 (2019): (Available online 1 April 2019)
Publisher : DiscoverSys Inc.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (354.727 KB) | DOI: 10.15562/ism.v10i1.367

Abstract

Background. Febrile neutropenia is a common complication in patient undergoing chemotherapy. Length Of Stay (LOS) is an important marker for disease severity and use of medical resources in febrile neutropenia. This study was done to find the risk factor affecting length of stay in solid cancer patients with febrile neutropenia post neoadjuvant/therapeutic chemotherapy.Method. This is a case control study without matching. Age ≥ 60 years, (Absolute Neutrofil Count) ANC level < 1,5 μL , comorbid,  Hb level <10 gr/dl, and albumin < 3 gr/dl, were related to LOS ( ≤ 5 days and > 5 days). Univariate (chi square) and multivariate (logistic regression) were used to analyse the statistic.Results. Forty six patients met inclusion-exclusion criteria were included in this study. ANC level in all patients were < 1,5 μL (100%). Hb level <10 gr/dl is statistically significant (P<0.05), whereas  age ≥ 60 years, and comorbid, albumin level < 3 gr/dl were not is statistically significant (P>0.05).Conclusion. Hb level < 10 gr/dl is the risk factor for LOS > 5 days in solid cancer patients with febrile neutropenia post neoadjuvant/therapeutic chemotherapy.
Co-Authors I. B. Tjakra Wibawa Manuaba Putu Anda Tusta Adiputra